US cancer start-up raised its money in Europe but tests its drug in Australia

EU PERSPECTIVES - Actithera, a US start-up developing radiation-based cancer drugs, raised most of its $75.5m from European investors and runs its labs in Oslo. Yet it will treat its first patients in Australia. Its founder Andreas Goutopoulos told EU Perspectives that Europe makes early trials too hard to start. Read more

Caption: Andreas Goutopoulos found investors in Europe, but not the rules he needs for early trials / Photo: Nordic Life Science Days